Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
10 sept. 2024 16h05 HE | Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Tony Tipton nommé au
Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des crises d’épilepsie
19 août 2024 11h30 HE | CROSSJECT
Communiqué de presse Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject en vue de la commercialisation de ZEPIZURE®, traitement d'urgence dans la prise en charge des...
Crossject appoints T
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment
19 août 2024 11h30 HE | CROSSJECT
Press Release Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation for Commercialization of ZEPIZURE® Epilepsy Rescue Treatment  Experienced executive to lead...
01_PrimaryLogo_Color_BlueX-100.jpg
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
13 août 2024 07h00 HE | Praxis Precision Medicines, Inc.
Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of...
Rapport_Logo_Color_RGB.png
Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
08 août 2024 07h00 HE | Rapport Therapeutics, Inc.
Rapport Therapeutics announces financial results for Q2 2024 and provides a business update, including progress on its precision neuroscience pipeline
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
07 août 2024 16h11 HE | Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Kaerus Logo
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
25 juil. 2024 05h00 HE | Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada
24 juil. 2024 08h05 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024
22 juil. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Logo_Horizontal_Fill_White_Transparent.png
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
26 juin 2024 16h05 HE | Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs